Full-Time

Lab Director of Molecular Pathology and Cytogenetics

Tenet Healthcare

Tenet Healthcare

10,001+ employees

Operates hospitals and clinics; revenue cycle

No salary listed

Detroit, MI, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • PhD in Life Science relevant to genetics, molecular biology, cancer biology, etc.
Responsibilities
  • In conjunction with Division of Laboratory Genetics Medical Director, assumes responsibility for effective planning, organization, direction and coordination of technical operations of the Molecular Genetics and Cytogenetics Laboratories, including pre and post-analytical functions.
  • In conjunction with Administrative Director, assumes responsibility for controlling productivity, fiscal responsibility and quality of results of test performed under his/her direction. Reports on a variety of specialized diagnostic laboratory tests and procedures.
  • Works with Medical Director to develop and implement technical policies, systems and procedures for the Medical Genetics Laboratory. Provides recommendations and input to policies, procedures and systems for other DMC laboratory functions. Cooperates with Site Medical and Administrative Directors by providing technical assistance for diagnostic testing performed within the Molecular Genetics and Cytogenetics Diagnostic Laboratories.
  • Participates in development and structure of Molecular Genetics and Cytogenetics Diagnostic Laboratory technical objectives; assists in development of specific short-term and long-range plans and programs including supporting budget and cost information.
  • Establishes and monitors all technical methods, processes and procedures; in conjunction with Administrative Director, cooperates with Medical Director to direct and implement department work schedules, staffing schedules, preventative maintenance programs and personnel requirements for the Molecular Genetics and Cytogenetics Diagnostics Laboratories.
  • Ensures validity, accuracy and analyses of all tests performed within the Molecular Genetics and Cytogenetics Diagnostics Laboratories.
  • Determines and develops department standards for test procedures. Prescribes appropriate test methods and ensures strict adherence to quality control programs within the Molecular Genetics and Cytogenetics Diagnostics Laboratories.
  • Participates in proficiency surveys to evaluate the Molecular Genetics and Cytogenetics Diagnostics Laboratory's performance.
  • Conducts and directs continuing assessment of test procedures; conducts and directs examination of new techniques and methods in order to determine appropriate changes to improve quality, reduce costs and enhance efficiency.
  • Directs technical training programs as required for employees, new employees, medical technology students, medical students and/or residents. Conducts periodic reviews with appropriate personnel to determine progress of individuals.
  • Establishes and maintains technical records and reports as required; issues reports regarding quality and quantity of clinical test procedures and results to management.
  • Maintains liaison with physicians and support staff, such as genetic counselors, nurses, and nurse practitioners. Prepares and distributes reports regarding discrepancies from standard test procedures and results to physicians and medical directors as indicated.
  • Develops and maintains contacts with educational institutions, professional organizations, government agencies, etc. to keep abreast of changes, developments and regulations related to clinical test procedures for diagnosis of illness and disease.
  • Assists in performance of experimental testing procedures as necessary. Submits results to Medical Director with recommendations regarding changes in methods to improve validity and accuracy of tests.
  • Appraises performance of subordinates and contributes to their development in conjunction with Medical Director and Administrative Director. Ensures adherence to work rules and recommends changes in status as appropriate.
  • Participates in development of operating and capital equipment budget for the Molecular Genetics and Cytogenetics Diagnostics Laboratories.
  • In conjunction with Administrative Director, assumes responsibility for ensuring that the Molecular Genetics and Cytogenetics Laboratory operates within assigned budget.
  • Attends and participates in meetings of board and committees related to administration of the core laboratory as appropriate and assigned.
Desired Qualifications
  • Previous experience in a clinical laboratory including administrative and managerial experience in technical activities to develop familiarity with laboratory technical activities and procedures involving Molecular Pathology or Cytogenetics is desirable

Tenet Healthcare operates a large network of hospitals and outpatient facilities across the United States, including 65 hospitals and about 500 other centers such as surgical hospitals, urgent care sites, and imaging centers. It also owns Conifer Health Solutions, which provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers, and other clients, helping them manage billing and payments and improve patient outcomes. The company earns revenue mainly from patient services and from Conifer’s administrative and financial services. Its goal is to deliver the right care, in the right place, at the right time, while improving patient outcomes and operational efficiency and serving as a trusted employer and partner.

Company Size

10,001+

Company Stage

IPO

Headquarters

Dallas, Texas

Founded

1967

Simplify Jobs

Simplify's Take

What believers are saying

  • Aging population drives demand for higher-acuity surgeries in ambulatory centers.
  • $1.9B CommonSpirit exit provides three years steady cash for debt reduction.
  • 10% core EBITDA growth projected for 2026 with conservative guidance baseline.

What critics are saying

  • Insider selling with zero purchases signals management confidence erosion.
  • HCA Healthcare's 800-center ASC expansion by 2027 intensifies competitive pressure.
  • Recent $2.25B debt issuance at 5.5-6% rates exposes Tenet to rate hike vulnerability.

What makes Tenet Healthcare unique

  • 518 ambulatory surgery centers provide higher-margin outpatient care versus traditional hospitals.
  • Conifer processes $25B annual net patient revenue for 600+ clients nationwide.
  • Full Conifer ownership enables AI-driven claims processing and denial management integration.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Mental Health Support

Paid Sick Leave

Paid Holidays

Paid Vacation

Health Insurance

Flexible Work Hours

Company News

Bitget
Apr 10th, 2026
Tenet's expansion into Conifer and outpatient growth: The true driver of earnings overlooked amid insider selling distractions.

Tenet's expansion into Conifer and outpatient growth: The true driver of earnings overlooked amid insider selling distractions. By: 101 finance Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now! Insider activity and leadership changes: context for Tenet Healthcare. Recent developments at Tenet Healthcare have drawn attention, particularly regarding insider transactions and changes in leadership. Paola Arbour, the company's Chief Information Officer, sold 18,168 shares in March 2024, bringing her total sales over the past year to 56,724 shares, with no corresponding purchases. This activity followed the departure of board member Stephen H. Rusckowski in November 2025. These events together highlight a trend of insider selling and boardroom turnover. For investors, the main question is whether these actions are significant indicators or simply background noise. The market has had time to process both the executive's share sales and the board change, with the CIO's transactions occurring more than a year ago and the board resignation announced last fall. During this period, Tenet has been undergoing a substantial strategic transformation, including the $2.4 billion divestiture of three South Carolina hospitals in early 2024 as part of a broader shift in its business portfolio. The company has also rapidly expanded its ambulatory care network, adding more than 50 new surgery centers within a year. Given these broader changes, market sentiment appears to be focused on Tenet's strategic direction rather than individual leadership exits. The company's recent price-to-earnings ratio of 17.28, which is below the sector median, suggests that investors are prioritizing operational execution and business transformation over management turnover. While insider selling is noteworthy, it may simply reflect routine financial planning or diversification by a long-serving executive, especially in the context of a company actively reinventing itself. Ultimately, expectations are being shaped by Tenet's strategic initiatives. The company's share price likely already factors in the reality of ongoing transformation. The real challenge lies not in executive departures, but in whether Tenet can continue to deliver on its ambitious plans. So far, the market seems to have absorbed the impact of leadership changes into the larger narrative of corporate evolution. Strategic portfolio realignment: the main value catalyst. While much attention has been paid to changes in Tenet's leadership, the real story lies in the company's disciplined approach to capital allocation and business restructuring. The major transactions completed in 2024 and 2026 are part of a cohesive strategy to strengthen Tenet's hospital and ambulatory platforms by divesting lower-margin assets and regaining control of essential services. * 2024 Hospital Sale: The $2.4 billion sale of three South Carolina hospitals to Novant Health marked a pivotal step in Tenet's transformation, as the company divested a total of 14 hospitals that year. The transaction provided a substantial cash boost to reduce debt and strengthen the balance sheet, despite resulting in a $222 million annual EBITDA reduction. The trade-off was considered worthwhile for the increased financial flexibility and streamlined operations. * 2026 Conifer Acquisition: In early 2026, Tenet finalized an agreement with CommonSpirit Health to acquire full ownership of Conifer Health Solutions. This $1.9 billion deal, which included payments and a capital redemption, eliminated a redeemable non-controlling interest and $885 million in liabilities. Gaining full control of Conifer enables Tenet to better integrate revenue cycle management with its operational objectives and invest in future growth. These strategic moves have fueled Tenet's expansion in ambulatory care. By the end of 2024, its United Surgical Partners International subsidiary had grown from 461 to 518 ambulatory surgery centers, adding 57 new facilities in just one year. This shift from traditional hospital operations to higher-margin outpatient care is the primary driver of value. Leadership changes, in this context, are secondary to the company's fundamental transformation, which is already reflected in its market valuation. Strategy spotlight: absolute momentum long-only approach. Tenet's stock performance has also been analyzed using a long-only absolute momentum strategy. This approach involves entering positions when the 252-day rate of change is positive and the closing price is above the 200-day simple moving average, and exiting when the price falls below the 200-day average, after 20 trading days, or upon reaching a take-profit of 8% or a stop-loss of 4%. The backtest, covering April 2024 to April 2026, yielded the following results: * Total Return: 26.91% * Annualized Return: 15.07% * Maximum Drawdown: 17.81% * Profit-Loss Ratio: 1.43 * Win Rate: 47.83% (11 wins out of 23 trades) * Average Holding Period: 8.87 days Financial performance and earnings outlook. Tenet's investment appeal is closely tied to its ability to deliver on financial targets. The company has a history of meeting or exceeding its own guidance, as demonstrated in January 2023 when it announced it would surpass the midpoint of its FY22 Adjusted EBITDA forecast. This track record of operational discipline is now under scrutiny as Tenet works to translate its strategic changes into sustainable earnings growth. The upcoming earnings report on April 30 will be a critical milestone, offering the first comprehensive look at the financial impact of the 2024 hospital divestitures and the 2026 Conifer acquisition. Investors will be watching to see if the rapid expansion of ambulatory services is beginning to offset the EBITDA lost from hospital sales and drive top-line growth. The market will be looking for evidence that Tenet can maintain its momentum as it pivots toward outpatient care. This sets up a classic risk/reward scenario. While the company's strategic moves are already priced into the stock, the true test will be Tenet's ability to convert its growing ambulatory platform and prudent capital management into consistent earnings growth. With the stock trading below the industry median, any failure to meet or exceed expectations could prompt a market reassessment. For now, Tenet is viewed as a capable operator meeting high expectations, but the upcoming earnings release will be a key indicator of whether it can sustain this performance. Key catalysts and risks: beyond executive departures. Looking ahead, Tenet's outlook is shaped by two main factors: a significant financial catalyst and ongoing governance risks. The most immediate catalyst is the execution of the Conifer transaction, which is structured as a multi-year arrangement. The deal, completed in early 2026, involves approximately $1.9 billion in payments from CommonSpirit to Tenet over three years. While this provides a steady cash flow, the real challenge will be how effectively management uses these funds to support further ambulatory expansion and reduce debt, ultimately driving sustained earnings growth. However, the ongoing pattern of insider selling remains a concern. Over the past year, there have been seven insider sales and no insider purchases, which could be interpreted as a lack of internal confidence. While the CIO's sales are not recent, continued insider selling or further leadership changes could raise questions about the company's strategic direction and financial health, potentially testing the market's current optimism. Ultimately, Tenet's future performance will depend on its ability to deliver sustained earnings growth as it scales its outpatient business and manages its substantial debt. The Conifer payments provide a financial buffer, but operational excellence remains essential. The upcoming earnings report will offer crucial insight into how these strategic initiatives are affecting the bottom line. In this environment, the impact of individual executive departures is overshadowed by the tangible financial outcomes of Tenet's multi-year transformation and the ongoing question of whether insider selling signals deeper concerns. Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Yahoo Finance
Mar 31st, 2026
Guggenheim raises Tenet Healthcare price target to $283, cites 90% return and 10% EBITDA growth outlook

Guggenheim has raised its price target on Tenet Healthcare Corporation from $271 to $283, maintaining a Buy rating on the stock. The firm cited the company's 90% return and described the first quarter as an "easy set-up" due to conservative guidance. It also views the projected 10% core EBITDA growth for 2026 as achievable. On the same day, Mizuho increased its price target from $235 to $265, maintaining an Outperform rating. The firm expects Tenet Healthcare to benefit from demographic shifts toward an ageing population and a focus on higher-acuity surgeries. Founded in 1969, Tenet Healthcare is a Texas-based diversified healthcare services company operating through Hospital Operations and Ambulatory Care segments.

Yahoo Finance
Feb 27th, 2026
Tenet Healthcare price target lifted to $270 by Truist after Q4 earnings beat

Tenet Healthcare Corporation has received positive analyst coverage following its fourth-quarter earnings release. Truist raised its price target to $270 from $240 on 17 February, maintaining a Buy rating after adjusting its model based on the company's fiscal Q4 results and 2026 guidance. Wells Fargo also increased its target to $265 from $229 on 16 February, keeping an Overweight rating. The firm cited strong capital return potential and market narrative alignment as key drivers, despite surprise at the stock's movement on previewed EBITDA figures. Tenet Healthcare reported Q4 net income of $371 million, or $4.22 per diluted share. Adjusted diluted earnings per share rose 36.6% to $4.70 compared to $3.44 in the previous year. The company operates through Hospital Operations and Ambulatory Care segments.

Healthcare Dive
Feb 2nd, 2026
Tenet regains full Conifer ownership as CommonSpirit exits for $1.9B

Tenet Healthcare has regained full ownership of its revenue cycle management subsidiary Conifer Health Solutions after CommonSpirit Health exited its stake. CommonSpirit will pay Tenet nearly $1.9 billion over three years to exit its services contract, offset by $540 million that Conifer will pay for CommonSpirit's 24% equity stake. The deal creates approximately $2.7 billion in total value for Tenet through cash payments, reduced balance sheet liability and additional equity value. Tenet's stock rose 2% following the announcement. Conifer processes roughly $25 billion in net patient revenue annually for over 600 clients. As sole owner, Tenet plans to increase investments in Conifer's artificial intelligence and automation capabilities, particularly in claims processing and managing disputes with insurers over claim denials.

Paul Hastings LLP
Dec 9th, 2025
Paul Hastings advises initial purchasers in Tenet Healthcare's $1.5B senior notes offering

Paul Hastings LLP advised the initial purchasers in Tenet Healthcare Corporation's $2.25 billion offering of senior notes. The transaction included $1.5 billion of 5.500% senior secured notes due 2032 and $750 million of 6.000% senior notes due 2033. Global Finance partner Corey Wright led the Paul Hastings team, which included of counsel Simon Cooke and associates Jessica Kelly and Joshua Rebollozo.